Thomas Bieber

48.9k total citations · 19 hit papers
479 papers, 27.7k citations indexed

About

Thomas Bieber is a scholar working on Dermatology, Immunology and Allergy and Immunology. According to data from OpenAlex, Thomas Bieber has authored 479 papers receiving a total of 27.7k indexed citations (citations by other indexed papers that have themselves been cited), including 277 papers in Dermatology, 216 papers in Immunology and Allergy and 165 papers in Immunology. Recurrent topics in Thomas Bieber's work include Dermatology and Skin Diseases (251 papers), Allergic Rhinitis and Sensitization (184 papers) and Asthma and respiratory diseases (107 papers). Thomas Bieber is often cited by papers focused on Dermatology and Skin Diseases (251 papers), Allergic Rhinitis and Sensitization (184 papers) and Asthma and respiratory diseases (107 papers). Thomas Bieber collaborates with scholars based in Germany, United States and Switzerland. Thomas Bieber's co-authors include Natalija Novak, Donald Y.M. Leung, Joerg Wenzel, Andreas Wollenberg, Kenji Kabashima, Jean‐Pierre Allam, Lisa A. Beck, Stephan Weidinger, Thomas Tüting and Alan D. Irvine and has published in prestigious journals such as Science, New England Journal of Medicine and Proceedings of the National Academy of Sciences.

In The Last Decade

Thomas Bieber

465 papers receiving 26.8k citations

Hit Papers

Revised nomenclature for ... 2003 2026 2010 2018 2004 2008 2018 2014 2003 500 1000 1.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Revised nomenclature for allergy for global use: Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003
    2004 1.6k citations Thomas Bieber, Johannes Ring et al. profile →
  2. Atopic Dermatitis
    2008 1.4k citations Thomas Bieber profile →
  3. Atopic dermatitis
    2018 1.1k citations Stephan Weidinger, Lisa A. Beck et al. profile →
  4. Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis
    2014 1.0k citations Lisa A. Beck, Thomas Bieber et al. profile →
  5. Atopic dermatitis
    2003 961 citations Thomas Bieber et al. profile →
  6. Consensus‐based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I
    2018 804 citations Andreas Wollenberg, Thomas Bieber et al. Journal of the European Academy of Dermatology and Venereology profile →
  7. Atopic Dermatitis
    2010 462 citations Thomas Bieber profile →
  8. Cellular and molecular immunologic mechanisms in patients with atopic dermatitis
    2016 440 citations Emma Guttman‐Yassky, Andreas Wollenberg et al. profile →
  9. Atopic dermatitis: an expanding therapeutic pipeline for a complex disease
    2021 394 citations Thomas Bieber profile →
  10. Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial
    2020 313 citations Eric L. Simpson, Andreas Wollenberg et al. profile →
  11. Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis
    2021 287 citations Thomas Bieber, Eric L. Simpson et al. profile →
  12. Interleukin‐13: Targeting an underestimated cytokine in atopic dermatitis
    2019 258 citations Thomas Bieber Allergy profile →
  13. Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial
    2021 250 citations Thomas Bieber, Jonathan I. Silverberg et al. profile →
  14. Tralokinumab plus topical corticosteroids for the treatment of moderate‐to‐severe atopic dermatitis: results from the double‐blind, randomized, multicentre, placebo‐controlled phase III ECZTRA 3 trial*
    2020 213 citations Jonathan I. Silverberg, D. Toth et al. British Journal of Dermatology profile →
  15. Biomarkers in atopic dermatitis—a review on behalf of the International Eczema Council
    2021 200 citations Jacob P. Thyssen, Thomas Bieber et al. profile →
  16. Trial of Nemolizumab in Moderate-to-Severe Prurigo Nodularis
    2020 173 citations Thomas Bieber, Andreas Wollenberg et al. profile →
  17. Type 2 chronic inflammatory diseases: targets, therapies and unmet needs
    2023 82 citations Cezmi A. Akdiş, Thomas Bieber et al. profile →
  18. Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebo-controlled phase III trials
    2023 72 citations Andrew Blauvelt, Jacob P. Thyssen et al. British Journal of Dermatology profile →
  19. Treatment of atopic dermatitis: Recently approved drugs and advanced clinical development programs
    2024 66 citations Svenja Müller, Laura Maintz et al. Allergy profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Thomas Bieber 17.4k 13.9k 7.6k 7.3k 4.0k 479 27.7k
Giampiero Girolomoni 9.9k 0.6× 3.8k 0.3× 3.2k 0.4× 12.5k 1.7× 3.7k 0.9× 558 23.7k
Stephen R. Durham 10.5k 0.6× 24.6k 1.8× 27.6k 3.6× 8.7k 1.2× 1.8k 0.5× 386 37.8k
Qutayba Hamid 4.7k 0.3× 10.0k 0.7× 22.8k 3.0× 12.5k 1.7× 2.0k 0.5× 518 37.8k
Thomas Ruzicka 11.9k 0.7× 3.7k 0.3× 2.6k 0.3× 6.2k 0.9× 3.2k 0.8× 672 26.2k
Marı́a José Torres 4.8k 0.3× 7.0k 0.5× 4.6k 0.6× 1.9k 0.3× 3.2k 0.8× 478 16.8k
Peter Valent 3.4k 0.2× 12.0k 0.9× 6.7k 0.9× 16.7k 2.3× 8.6k 2.2× 900 40.5k
Enno Christophers 6.0k 0.3× 2.0k 0.1× 2.6k 0.3× 10.1k 1.4× 2.0k 0.5× 362 18.9k
Yong-Jun Liu 3.4k 0.2× 2.9k 0.2× 3.2k 0.4× 19.6k 2.7× 1.6k 0.4× 208 28.1k
Lawrence B. Schwartz 1.6k 0.1× 6.9k 0.5× 6.1k 0.8× 11.5k 1.6× 4.1k 1.0× 263 22.2k
Claus Bachert 2.6k 0.1× 18.9k 1.4× 18.9k 2.5× 4.0k 0.5× 1.8k 0.5× 702 33.3k

Countries citing papers authored by Thomas Bieber

Since Specialization
Citations

This map shows the geographic impact of Thomas Bieber's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas Bieber with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas Bieber more than expected).

Fields of papers citing papers by Thomas Bieber

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas Bieber. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas Bieber. The network helps show where Thomas Bieber may publish in the future.

Co-authorship network of co-authors of Thomas Bieber

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas Bieber. A scholar is included among the top collaborators of Thomas Bieber based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas Bieber. Thomas Bieber is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Bieber, Thomas, Amy S. Paller, Lisa A. Beck, et al.. (2025). Lebrikizumab vs Other Systemic Monotherapies for Moderate-to-Severe Atopic Dermatitis: Network Meta-analysis of Efficacy. Dermatology and Therapy. 15(3). 615–633. 7 indexed citations
2.
3.
Bieber, Thomas, et al.. (2024). Emerging Biologic Therapies for the Treatment of Atopic Dermatitis. Drugs. 84(11). 1379–1394. 11 indexed citations
4.
Bieber, Thomas. (2024). The paradigm shift in drug development for atopic dermatitis: Addressing the variables of the equation leading to disease modification. Annals of Allergy Asthma & Immunology. 134(2). 144–150. 1 indexed citations
5.
Müller, Svenja, Laura Maintz, & Thomas Bieber. (2024). Treatment of atopic dermatitis: Recently approved drugs and advanced clinical development programs. Allergy. 79(6). 1501–1515. 66 indexed citations breakdown →
6.
Silverberg, Jonathan I., David Rosmarin, Raj Chovatiya, et al.. (2024). The regulatory T cell-selective interleukin-2 receptor agonist rezpegaldesleukin in the treatment of inflammatory skin diseases: two randomized, double-blind, placebo-controlled phase 1b trials. Nature Communications. 15(1). 9230–9230. 12 indexed citations
7.
Blauvelt, Andrew, Jacob P. Thyssen, Emma Guttman‐Yassky, et al.. (2023). Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebo-controlled phase III trials. British Journal of Dermatology. 188(6). 740–748. 72 indexed citations breakdown →
8.
Wollenberg, Andreas, et al.. (2023). A detailed look at the European Medicines Agency's recommendations for use of Janus kinase inhibitors in patients with atopic dermatitis. Journal of the European Academy of Dermatology and Venereology. 37(10). 2041–2046. 8 indexed citations
9.
Weidinger, Stephan, Thomas Bieber, Michael J. Cork, et al.. (2023). Safety and efficacy of amlitelimab, a fully human nondepleting, noncytotoxic anti-OX40 ligand monoclonal antibody, in atopic dermatitis: results of a phase IIa randomized placebo-controlled trial. British Journal of Dermatology. 189(5). 531–539. 61 indexed citations
10.
Maintz, Laura, Thomas Welchowski, Nadine Herrmann, et al.. (2023). IL‐13, periostin and dipeptidyl‐peptidase‐4 reveal endotype‐phenotype associations in atopic dermatitis. Allergy. 78(6). 1554–1569. 21 indexed citations
11.
Krohn, Inge Kortekaas, et al.. (2023). Immunoglobulin E autoantibodies in atopic dermatitis associate with Type‐2 comorbidities and the atopic march. Allergy. 78(12). 3178–3192. 15 indexed citations
12.
Simpson, Eric L., Emma Guttman‐Yassky, Lawrence F. Eichenfield, et al.. (2023). Tralokinumab therapy for moderate‐to‐severe atopic dermatitis: Clinical outcomes with targeted IL‐13 inhibition. Allergy. 78(11). 2875–2891. 21 indexed citations
13.
Siegfried, Elaine C., Thomas Bieber, Eric L. Simpson, et al.. (2021). Effect of Dupilumab on Laboratory Parameters in Adolescents with Atopic Dermatitis: Results from a Randomized, Placebo-Controlled, Phase 3 Clinical Trial. American Journal of Clinical Dermatology. 22(2). 243–255. 18 indexed citations
14.
Sakai, Takashi, Nadine Herrmann, Laura Maintz, et al.. (2021). Altered Serum Phospholipids in Atopic Dermatitis and Association with Clinical Status. SHILAP Revista de lepidopterología. 2(2). 100092–100092. 10 indexed citations
15.
Silverberg, Jonathan I., D. Toth, Thomas Bieber, et al.. (2020). Tralokinumab plus topical corticosteroids for the treatment of moderate‐to‐severe atopic dermatitis: results from the double‐blind, randomized, multicentre, placebo‐controlled phase III ECZTRA 3 trial*. British Journal of Dermatology. 184(3). 450–463. 213 indexed citations breakdown →
16.
Smith, Paul, et al.. (2019). AB0042 PRECLINICAL EVALUATION OF JAK1 SELECTIVE INHIBITORS INCB039110 AND INCB054707 AS TARGETED THERAPY OF CUTANEOUS LUPUS ERYTHEMATOSUS. Annals of the Rheumatic Diseases. 78. 1487–1487. 3 indexed citations
17.
Novak, Natalija, Wenming Peng, Thomas Bieber, & Cezmi A. Akdiş. (2013). F cε RI stimulation promotes the differentiation of histamine receptor 1‐expressing inflammatory macrophages. Allergy. 68(4). 454–461. 19 indexed citations
18.
Hagemann, Tobias, Thomas Bieber, Ioanna Maria Dimitriou, et al.. (2013). Characterization of different courses of atopic dermatitis in adolescent and adult patients. Allergy. 68(4). 498–506. 221 indexed citations
19.
Bieber, Thomas, Michael J. Cork, & Sakari Reitamo. (2012). Atopic dermatitis: a candidate for disease‐modifying strategy. Allergy. 67(8). 969–975. 94 indexed citations
20.
Ortonne, J P, JC Prinz, Thomas Bieber, et al.. (2006). 0.3% Tacrolimus gel and 0.5% Tacrolimus cream show efficacy in mild to moderate plaque psoriasis: Results of a randomized, open-label, observer-blinded study. Acta Dermato Venereologica. 86(1). 29–33. 26 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Giampiero Girolomoni Breakdown of academic impact, for papers by Stephen R. Durham Breakdown of academic impact, for papers by Qutayba Hamid Breakdown of academic impact, for papers by Thomas Ruzicka Breakdown of academic impact, for papers by Marı́a José Torres Breakdown of academic impact, for papers by Peter Valent Breakdown of academic impact, for papers by Enno Christophers Breakdown of academic impact, for papers by Yong-Jun Liu Breakdown of academic impact, for papers by Lawrence B. Schwartz Breakdown of academic impact, for papers by Claus Bachert
Rankless by CCL
2026